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ABSTRACT 
Autophagy is important for hepatic homeostasis, nutrient regeneration and organelle quality 
control.  We investigated the mechanisms by which liver injury occurred in the absence of 
autophagy function.  We found that mice deficient in autophagy due to the lack of Atg7 or 
Atg5, key autophagy-related genes, manifested intracellular cholestasis with increased levels 
of serum bile acids, a higher ratio of TMCA/TCA in the bile, increased hepatic bile acid load, 
abnormal bile canaliculi and altered expression of hepatic transporters.  In determining the 
underlying mechanism, we found that autophagy sustained and promoted the basal and 
upregulated expression of Fxr in the fed and starved conditions, respectively.  Consequently, 
expression of Fxr and its downstream genes, particularly Bsep, and the binding of FXR to the 
promoter regions of these genes, were suppressed in autophagy-deficient livers.  In addition, 
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co-deletion of Nrf2 in autophagy deficiency status reversed the FXR suppression.  
Furthermore, the cholestatic injury of autophagy-deficient livers was reversed by 
enhancement of FXR activity or expression, or by Nrf2 deletion.  Conclusions: Together 
with earlier reports that FXR can suppress autophagy our new findings indicate that 
autophagy and FXR form a novel regulatory loop and deficiency of autophagy causes 
abnormal FXR functionality, leading to the development of intracellular cholestasis and liver 
injury.   
 
INTRODUCTION 
Macroautophagy, hereafter referred to as autophagy, is an evolutionarily conserved 
cellular degradation mechanism dependent on the lysosome (1).  It is important for nutrient 
regeneration, organelle turnover, clearance of aggregated cellular materials, and defense 
against intracellular pathogens.  Autophagy is well regulated for the need for nutrients and 
energy, and the catabolic function of autophagy is often coupled with the anabolic need of the 
cell (2-4).  However, the regulation of metabolism by autophagy via mechanisms other than 
recycling macromolecules or organelles is not well studied.   
Autophagy deficiency can result in multiple pathological conditions (5).  Deficiency in 
hepatic autophagy causes severe hepatomegaly and liver injury, accompanied with 
inflammation fibrosis and tumorigenesis (6-8).  How loss of autophagy function leads to the 
pathological consequences in the liver and other tissues is not well understood but is likely 
caused by more than just failure in degradation of pathogenic constituents.  In the liver it is 
found that the accumulation of p62/SQSTM1 disabled the ubiquitination process of NRF2 (6).  
As the result, NRF2 is accumulated and contributes to the liver injury phenotype (6-8).   
However, it is not known how NRF2 mediates hepatic injury.  We have found that NRF2 
can control the release of HMGB1 from hepatocytes (8).  HMGB1 affects some of the 
phenotypic presentations of the autophagy-deficient liver, including ductular reaction and 
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tumor development, but not the injury.  Thus there would be other NRF2-directed events that 
contribute to the development of liver injury.  NRF2 is known as a transcription activator, 
binding to the promoter region of many target genes at the sequence site known as 
antioxidant response element (ARE) (9-11).  NRF2 is often activated in response to oxidative 
stress or electrophilic stress (11, 12), and many of the target genes are involved in anti-
oxidative response.  In addition, it transcriptionally activates a number of enzymes for 
oxidation/reduction, conjugation and transportation of drugs (11, 13).  These activities are 
generally associated with a cellular protective role of NRF2.  However, alterations in gene 
functions caused by NRF2 that may result in tissue injury have not been defined.   
The present study found that autophagy deficiency can lead to multiple defects related to 
bile acids (BA) synthesis, secretion and regulation, and autophagy deficient mice presented a 
phenotype consistent with intracellular cholestasis, which can contribute to the liver injury in 
these mice.  Notably NRF2 is instrumental in the development of these phenotypes.  
Moreover, FXR stands out as an important target regulated by autophagy function in both fed 
and starved conditions.  Recovery of FXR functionality in autophagy deficient livers is able 
to remedy the disturbed BA metabolism and the cholestasis phenotype.  Since FXR can 
suppress the expression of some autophagy genes under nutrient replete condition (14, 15), 
the ability of autophagy to stimulate Fxr expression at basal and starvation condition indicate 
the two functions can form a regulatory loop, which is important for the homeostasis of the 
liver.   
 
Materials and Methods 
Mice and reagents.  Mice with hepatic deletion of Atg7 or Atg5, with or without Nrf2 co-
deletion, were bred as detailed in the Supplemental Methods.  Mice of both genders at the age 
of 9-week old were studied.  All animal procedures were approved by the institutional animal 
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care and use committee (IACUC) of the Indiana University.  Antibodies used in this study are 
shown in Supplemental Table S1.  Gene-specific primers (Supplemental Table S2) were 
ordered from Integrated DNA Technologies, Inc (Coralville, Iowa).   
 
Biochemical, molecular, immunological and imaging assays.  Blood chemistry and 
bile acids were analyzed using commercial available kits or by mass spectrometry.  Histology 
and electron microscopy, immunoassys, qRT-PCR and CHIP analysis were performed using 
standard protocols.  Additional details can be found in the Supporting Information.  
 
Statistical analysis.  Statistical analysis was performed using Sigma Stat 3.5 with 
information on distribution fitting and variance that were appropriate for the test selected.  
Results were expressed as the means ± s.e.m.  P values from at least 3 independent 
determinations or samples per treatment were calculated using One-Way ANOVA followed 
by Duncan’s post-hoc analysis (for multiple group comparisons) or two-tailed Student’s t-test 
(for paired group comparisons).  A P value of <0.05 was considered significant.   
 
RESULTS 
Autophagy deficiency caused NRF2-dependent cholestasis  
Mice with autophagy deficiency in the liver developed hepatic injury (6, 7), but the nature 
of the injury and the involved mechanism were not known.  Notably, the injury can be largely 
corrected by the co-deletion of Nrf2 (6, 7).  How could a normally anti-oxidative NRF2 
become pathogenic in the autophagy-deficient condition is not understood.  We found that 
mice deficient in hepatic Atg7 (Atg7
Hep
) had a significantly elevated level of serum bile acids 
(BA) but not total bilirubin (Fig. 1A), and there was a lack of jaundice and obvious external 
bile duct blockage, all suggesting the presence of intracellular cholestasis.  Concomitantly, 
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there was an elevated level of cholesterols but not triglycerides (Fig. 1D), consisting with an 
inhibition of synthetic conversion of cholesterol to BA during cholestasis.  As reported before, 
live injury as measured by serum level of ALT (Fig. 1C) was significant.  Together with the 
histological evidence of massive ductular reaction reported in our earlier studies (8), these 
findings suggest that the autophagy deficient livers had developed cholestatic injury.   
 
Deletion of another key autophagy gene, Atg5, in the liver (Atg5
Hep
) led to the same 
biochemical (Fig. S1) and histological (8) alterations.  Remarkably, in both Atg7
Hep
 and 
Atg5
Hep
 mice, co-deletion of Nrf2 corrected the abnormal levels of BA and cholesterol (Fig. 
1A-C, Fig. S1), implicating that NRF2 contributed to the development of cholestasis.  
 
Using a tamoxifen-inducible mouse strain of Atg7 deletion (Atg7
Hep-ERT2
), we found that 
elevation of blood BA was a rapidly developed early event that followed autophagy gene 
deletion in hepatocytes (Fig. 1D).  Deletion of Atg7 in the adult livers was apparent in 7 days 
after the administration of tamoxifen (see below).  Elevations of blood BA, cholesterol and 
ALT were progressed in parallel, but BA elevation was earlier at Day 10 after tamoxifen 
treatment, followed by the elevations of cholesterol and ALT at Day 12, and Day 15, 
respectively.   
 
While the BA levels in the gallbladder and the intestine were not changed, BA level in the 
liver was significantly increased (Fig.1E), indicating an accumulation in the hepatocyte.  The 
total BA pool was only mildly increased in autophagy deficient mice (Fig. 1F), due to the 
larger size of the intestinal BA pool, which diminished the relative contribution of the hepatic 
BA to the total pool.  However, when the total pool is normalized to the body weight, it was 
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significantly higher in autophagy deficient mice (Fig. 1F), indicating an overall elevation of 
BA in the digestive track relative to the body size.   
 
Bile acids metabolism was altered in autophagy deficient livers.  
Bile acids are synthesized in hepatocytes via the classical and alternative pathways (Fig. 
S2A).  All four key genes involved in BA synthesis, Cyp7a1 and Cyp8b1 of the classical 
pathway, and Cyp27a1 and Cyp7b1 of the alternative pathway, were reduced in expression in 
Atg7-deficient livers (Fig. 2A. Fig. S2B) or in Atg5-defient livers (Fig. S2C).  Expression of 
Hsd3b7, but not Akr1d1, was also reduced in expression (Fig. 2B-C).  These results could 
rule out that the elevated BA levels in the liver and in the blood were due to an increased 
expression of key synthesis enzymes.  The results might be more compatible with the 
presence of feedback suppression during cholestasis.  In addition, Nrf2 co-deletion 
significantly reversed the change of these genes except Cyp7b1 (Fig. 2A-C, FigS2B), 
indicating that Nrf2 could be largely responsible for these expressional changes, although 
Cyp7b1 seemed to be affected independently.   
 
The composition of different BA species in the bile was thus analyzed (Fig. 2D-E).  The 
majority of the mouse BA in the bile was conjugated with taurine, which did not seem to 
change in autophagy-deficient mice.  There seemed to have a reduction in unconjugated 
primary BA and in conjugated or unconjugated secondary BA in autophagy deficiency.  
However, the most significant change was the increase in conjugated α- and β-muricholic 
acids (TMCA), and the corresponding decrease in conjugated cholic acids (TCA), leading to 
a higher TMCA/TCA ratio in the autophagy-deficient mice.  In contrast, the control mice had 
a lower TMCA/TCA ratio as previously reported (16-19).  This suggested an imbalance in 
the synthesis of different BA species in autophagy-deficient livers.   
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This change in TMCA/TCA ratio is likely due to the mechanism that the synthesis of 
cholic acid (CA) but not chenodeoxycholic acid (CDCA) is dependent on CYP8B1 (Fig. 
S2A).  In addition, the alternative pathway, which contributes mainly to CDCA, would be 
less affected by changes in mRNA expression of the relevant enzymes than by their post-
transcriptional regulations (20).  Together, these conditions led to a relatively higher level of 
CDCA, and thus a higher level of muricholic acids, which are derived from CDCA, similar to 
what has been reported in Cyp8b1-deficient mice (19).   
 
Nrf2 caused the absence of BSEP in autophagy deficient livers 
To explore the potential mechanism of cholestasis in the autophagy-deficient livers, we 
examined the expression of BA transporters.  More than 95% of the synthesized BA are 
secreted into the bile canaliculi through bile salt export pump (BSEP/ABCB11), at the apical 
side of hepatocytes (21, 22), which is a major contributor of the bile acid-dependent bile flow.  
We found a greatly diminished protein expression of BSEP in both Atg7
Hep
 and Atg5
Hep
 
livers (Fig. 3A-B).  Immunostaining for BSEP demonstrated a distinct bile canaliculi pattern 
in normal, but not in autophagy-deficient, livers (Fig. 3C).  Co-deletion of Nrf2 restored the 
expression (Fig. 3A-C).  Deficiency of BSEP could be at least in part responsible for the 
cholestasis (22, 23). 
Three other apical transporters, Mrp2/Abcc2, Mdr1a/Abcb1a, and Mdr1b/Abcb1b were 
increased in mRNA expression (Fig. 3D, Fig. S3A), likely as a result of compensatory 
response to Bsep downregulation (22).  These transporters account for only a low level of bile 
acid secretion, but were mainly involved in the secretion of bilirubin, GSH and organic ions 
(24).  Two other apical transporters, Mdr2/Abcb4, mainly for the secretion of phospholipids 
(25), and Abcg5 and Abcg8, which form heterodimer for the secretion of cholesterol (26), did 
not present significant changes in autophagy deficient livers (Fig. 3D).   
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As seen in a variety of cholestatic conditions, the mRNA expression of basolateral-
systemic transporters (Mrp3, Mrp4, and Ostβ) (Fig. 3E, Fig. S3B-C) was increased in both 
Atg7
Hep
 and Atg5
Hep
 livers for enhanced efflux of bile acids into the system circulation, 
which was consistent with the elevated BA in the blood (Fig. 1A).  Concordantly, there was 
an anticipated reduction in the expression of the basolateral enterohepatic transporters (Oatp, 
Ntcp) (Fig. 3F) in order to reduce the reabsorption of BA from the enterohepatic circulation.  
Co-deletion of Nrf2 also corrected the alterations in the expression of basolateral transporters 
(Fig. 3E-F, Fig. S3B-C), thus supporting the notion that Nrf2 could mediate these changes 
under autophagy deficiency.   
 
Autophagy deficiency caused abnormalities in bile canaliculi  
The immunostaining pattern of MRP2, an apical transporter, seemed to be enhanced and 
was slightly distorted at certain locations (Fig. 4A).  Electron microscopic analysis of the 
Atg7-deficient livers confirmed that bile canaliculi were swollen and dilated (Fig. 4B).  Many 
of the canaliculi had fewer or no microvilli; and lamellar materials or proteinaceous deposits 
were observed inside the canaliculi.  The alteration also involved the tight junction as shown 
by the staining for ZO-1 (Fig. 4C).  Normal ZO-1 staining showed a mixed pattern of puncta 
and fine lines along the hepatocyte boards.  However, in Atg7-deficient livers, a coarse, 
expanded, and twisted pattern was observed, which suggested a change in the bile canaliculi 
(27).  Notably the ultrastructural alterations in bile canaliculi and the irregular MRP2 and 
ZO-1 immunostaining patterns were largely corrected when Nrf2 was co-deleted (Fig. 4A-C).  
While the cannalicular structure and the tight junctions were compromised, the adherens 
junction and the cytoskeletal components seemed to be largely preserved as shown by the 
normal β CATENIN expression pattern (Fig. 4D), and the normal F-actin staining pattern 
(Fig. 4E).   
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Autophagy regulates FXR expression in fed and starved conditions 
Regulation of BA metabolism is complicated and is affected by multiple factors.  We 
decided to focus on the potential role of FXR in the present case not only because FXR 
regulates BA metabolism at multiple points, including the transcriptional expression of Bsep 
and several other genes whose promoters contain FXR response elements (FXRE)(20, 28-32), 
but also because FXR had been shown to interplay with autophagy function in a negative 
fashion under the fed condition (14, 15).  Autophagy function could in turn affect FXR; but 
this possibility had not been studied.   
 
We thus examined whether FXR expression could be affected by the treatment of 
rapamycin or starvation.  Either treatment blocks mTOR function and stimulates autophagy 
in a physiologically relevant manner from the yeast to the mammals (1).  Indeed, we found 
that FXR expression was upregulated in wild type mice following such treatments (Fig. 5A-
B).  In addition, some FXR targets, such as Pepck, ApoE, and Baat, were significantly 
upregulated in both treatments, whereas other targets were only significantly upregulated in 
starved condition, such as Shp and Slc27a5/Bacs, or in neither condition, such as Bsep, in the 
same time frame (Fig. 5B).  
 
We then compared the FXR expression in autophagy-competent and autophagy-deficient 
mice under the fed condition.  In contrast to the condition of autophagy activation, hepatic 
expression of FXR was significantly reduced in both Atg7
Hep
 and Atg5
Hep
 mice (Fig. 5C, 
Fig. S4A-B).  To rule out that this FXR reduction was a long-term adaptive response to 
autophagy deficiency we analyzed the time course of such changes in the inducible Atg7
ΔHep-
ERT2
 mice under the fed condition.  FXR and BSEP expression decreased rapidly in response 
to Atg7 deletion following tamoxifen induction (Fig. 5D) in the same time frame as the 
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elevation of SQSTM1/p62 and NQO1, the two known molecules upregulated in autophagy-
deficient livers (6, 7).  Furthermore, following tamoxifen treatment the inducible Atg7
ΔHep-
ERT2
 mice failed to upregulate FXR level in starvation (Fig. 5E).  Taken together these results 
supported the regulatory role of autophagy in FXR expression under both fed and starved 
conditions.   
 
Downregulation of FXR functionality is regulated by NRF2 in autophagy-deficient 
livers. 
NRF2 can transcriptionally activate a number of genes including Sqstm1 in autophagy 
deficient livers (6, 9-11).  Deletion of Nrf2 in autophagy-deficient livers reduced the 
accumulated SQSTM1 level (Fig. 6A, Fig. S5A-B).  Conversely, NRF2 was important for the 
downregulation of FXR as co-deletion of Nrf2 in autophagy deficient livers led to a 
significant restoration of FXR expression at both protein and mRNA (Fig. 6A-B, Fig. S4B) 
levels.  Co-deletion of Nrf2 was able to significantly reverse the expressional change of the 
major FXR targets, including Shp, Bsep, Slc27a5/Bacs (Fig. 6C, Fig. S4C-D) and Ntcp (Fig. 
3F) in Atg7 or Atg5-deficient livers.  The downregulation of Baat was not reversed by Nrf2 
deletion (Fig. 6C), suggesting that it might be subjected to additional regulation.  We further 
showed that NRF2 activation alone pharmacologically or genetically could cause 
downregulation of FXR (Fig. S6).  Such activations do not cause liver injury or autophagy 
deficiency (8).  
 
FXR induces gene transcription by directly binding to FXRE (28, 30, 31).  CHIP analysis 
effectively detected the binding of FXR to the FXRE sequence in the promoters of Shp, Bsep 
and Ostβ genes (Fig. 6D), but not in a coding region (Fig. 6E), in the normal livers.  
However, FXR binding to the target gene promoters was suppressed in autophagy-deficient 
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livers, which could be significantly reversed by co-deletion of Nrf2 (Fig. 6D).  These data 
thus suggested that NRF2 negatively regulated FXR binding to its target gene promoters, 
possibly by reducing its expression level.  Additionally, FXR binding to these sites was 
elevated in the livers deficient in Nrf2 alone (Fig. 6D), suggesting that NRF2 could provide a 
counterbalance to FXR activity even at the basal level.   
 
The discrepancy between reduced FXR binding to the FXRE of Ostβ (Fig. 6D) and an 
increased expression of this gene (Fig. 3E), and the ability of Nrf2 co-deletion to reverse 
these changes suggested that Nrf2 had an independent but more dominant control on Ostβ 
expression in the autophagy deficiency setting.  Indeed, there is an Nrf2-binding ARE 
sequence in the Ostβ promoter (Khambu and Yin, unpublished observations).   
 
Enhancement of FXR expression or activity alleviated cholestatic injury in 
autophagy-deficient livers 
Because FXR can regulate the expression of genes involved in BA synthesis, secretion 
and reabsorption, downregulated FXR expression and activity in autophagy deficient livers 
could be an important contributing mechanism for the cholestasis in these livers.  
 
To further examine this hypothesis, we treated 4-week old Atg7-deficient mice, which 
had about 40% of FXR expression (Fig. 5C), with a potent and selective nonsteroidal FXR 
agonist, GW4064 (33, 34) (Fig. 7A).  FXR activity was stimulated based on the restored 
mRNA expression of its target genes, Shp, Bsep, Slc27a5/Bacs, and Baat (Fig. 7B).  Re-
expression of the BSEP molecules was also confirmed by immunoblotting and 
immunostaining (Fig. 7C-D), which showed a normal canalicular pattern.  Note that 
SQSTM1 expression was not significantly changed at the protein or mRNA level by 
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GW4064 treatment (Fig. S5C-D).  Histological analysis of the liver in treated Atg7
ΔHep
 mice 
revealed a significant reduction in the severity of ductular reaction and the number of CK19-
positive ductular cells (Fig7E).  Together with these changes, a significant reduction in blood 
bile acids and ALT levels, and improved liver/body weight ratio were observed (Fig. 7F), 
indicating that GW4064 was able to significantly correct cholestasis and liver injury caused 
by autophagy deficiency.   
 
Alternatively, we administrated a constitutively activated Fxr construct, Ad-VP16-Fxr 
(17), at the time when the Atg7 gene was deleted in the inducible Atg7
ΔHep-ERT2
 mice (Fig. 8A).  
This treatment elevated the mRNA levels of Fxr, Shp, and Bsep in 10 days (Fig. 8B).  The 
normalized BSEP expression was confirmed by immunoblotting (Fig. 8C) and 
immunostaining (Fig. 8D) assays in mice given Ad-VP16-Fxr.  Similar to the treatment with 
GW4064, increased expression of FXR did not cause changes in SQSTM1 expression at the 
protein or mRNA level (Fig. 8C, Fig. S5E-F).  The cholestasis was reversed as shown by the 
reversion of the elevated expression of Mrp4 to the normal level (Fig. 8B), the reduced 
ductular reaction (Fig. 8D) and the normalization of blood BA level (Fig. 8E).   
Taken together, autophagy deficiency in the liver led to the down-regulated expression 
of FXR and its target molecules, including BSEP, which could contribute to intracellular 
cholestasis.  Enhancing FXR activities resorted BSEP expression, normalized blood BA level 
and ameliorated the injury phenotype.  This study also indicated that an important function of 
normal autophagy is to maintain FXR functionality.  
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DISCUSSION 
Autophagy regulates FXR expression and activity 
A key finding of this study is the regulation of FXR expression and function by 
autophagy and the pathological consequence of the failure of such a regulation.  We showed 
here that autophagy sustained FXR expression in fed condition and promoted FXR 
upregulation in starved condition.  The expression of the target genes of FXR was affected 
correspondingly.  Previous studies have shown that FXR can act as an inhibitory mechanism 
for autophagy in both fed and starved condition by regulating the transcriptional levels of 
several autophagy-related genes, such as Lc3b and Atg7 (14, 15).  Our data now show that 
autophagy and FXR can form a regulatory loop in which autophagy can maintain FXR 
functionality and FXR signaling can serve as a feedback suppression mechanism for 
autophagy (Fig. 8F).  This dynamic relationship could provide an overall homeostasis of the 
two functions.   
 
The reduced FXR functionality in autophagy-deficient livers could be resulted from 
several mechanisms.  First, the transcriptional level of Fxr was reduced.  Second, the ability 
of FXR to bind to FXRE in target genes was reduced, which would be in part due to the 
reduced level of FXR.  Thirdly, the ratio of TMCA/TCA was increased in autophagy-
deficient mice.  Since TMCA is an antagonist of FXR (16) a higher TMCA/TCA ratio can 
lead to an enhanced antagonism against FXR activity as noted previously (16).   
 
FXR expression decreased at both protein and mRNA levels, rapidly following the 
deletion of Atg7 or Atg5 no matter whether the deletion occurred at the embryonic or adult 
stage.  NRF2 seems to mediate the mechanism, by which autophagy deficiency represses 
FXR functionality.  NRF2 also affected the FXR binding to FXRE in the promoters of the 
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target genes.  On the other hand, the mechanism by which activated autophagy promotes 
FXR expression following starvation or rapamycin treatment has yet to be defined.  
Interestingly, a previous study had shown that NRF2 could also activate FXR by a non-
transcriptional mechanism via promoting its deacetylation in a cellular protection mode (35).  
It may be speculated that NRF2 might be involved in FXR regulation in both directions.  But 
if that would be the case, the context, the mode of action and the way NRF2 is activated, 
would be all very different.   
 
Being a major intracellular receptor of BA, FXR is activated by BA and in turn negatively 
regulates BA metabolism.  FXR downregulation in autophagy-deficient condition could be a 
major contributing factor to the observed cholestasis phenotype.  FXR normally upregulates 
BSEP to promote BA secretion (18, 36).  We did not see the upregulation of BSEP in starved 
or rapamycin-treated livers where FXR was upregulated.  But a significant suppression of 
BSEP expression was seen in autophagy-deficient condition.  It seems that the influence of 
FXR on BSEP expression could be context-dependent and affected by other signals.  
Abnormal BSEP function is correlated with cholestasis (22, 23).  FXR downregulation would 
likely be not the only factor causing cholestasis.  However, augmentation of FXR 
functionality significantly restored BSEP expression, and reduced cholestasis and injury.   
 
Since bile acid metabolism is closely coupled with cholesterol catabolism, autophagy may 
have a role in regulating cholesterol metabolism, which is evident from the elevated serum 
cholesterol level in autophagy-deficient mice (Fig. 1E, Fig. S1E).  FXR is also broadly 
engaged in cholesterol, lipid and glucose metabolism in addition to bile acids metabolism (20, 
30, 37, 38).  Indeed, FXR upregulation under the condition of autophagy activation is most 
prominently associated with the upregulation of Pepck and ApoE, which are involved in 
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metabolism of gluconeogenesis and lipids, respectively.  It is thus conceivable that a normal 
autophagy function could have impacts on these processes via FXR.  The functional 
significance of FXR upregulation and downregulation under different autophagy status may 
thus be distinct.   
 
Autophagy regulates bile acids metabolism and autophagy-deficient liver injury is 
related to cholestasis. 
Hepatic deficiency-induced liver injury is well documented (6-8) but the nature of the 
injury was not clear.  Our findings indicate that cholestasis can be a major contributing factor 
to the liver injury based on the elevated bile acids level in the blood, the elevated hepatic bile 
acids level, the altered bile acid composition in the bile, the repressed expression of bile acids 
synthesis genes, the altered expression of both apical and basal-lateral transporters and the 
altered bile canalicular structure.  These changes led us to determine FXR as a key 
mechanistic factor in the pathogenesis, and to identify the role of autophagy in the 
homeostasis of the FXR-bile acid metabolism.   
 
Most of the metabolic functions of autophagy are known to be mediated by the recycling 
of nutrients or by the direct removal of unwanted organelles (2-4).  However, the homeostatic 
role of autophagy in bile acids metabolism as shown in this study is mediated by a series of 
signaling events that are characterized by the alteration in FXR functionality.  This 
demonstrates a new pattern of metabolism regulation by autophagy and suggests that the 
impact of autophagy on metabolism can be much broader than previously thought.   
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While the downregulation of BSEP can be a direct consequence of FXR downregulation, 
the cause of the altered expression of BA synthesis genes can be more convoluted.  The four 
key synthesis genes (Cyp7a1, Cyb8b1, Cyp27a1 and Cyp7b1) in the classical and alternative 
pathways were downregulated in the autophagy-deficient livers, likely in response to elevated 
hepatic BA levels.  But the signaling leading to these changes have yet to be clearly depicted 
since the usual inhibitory signaling mediated by FXR might not work in the face of reduced 
FXR functionality in the autophagy-deficient livers.  Expression of Cyp7a1, Cyp8b1 and 
Cyp27a1 in autophagy-deficient livers was restored with the co-deletion of Nrf2, which might 
simply reflect the fact that NRF2 corrected the cholestasis.  Interestingly, Cyp7b1 expression 
was not restored by co-deletion of Nrf2, suggesting that its expression has more complicated 
regulatory mechanisms in autophagy deficient livers.   
 
One interesting but still yet to be fully investigated observation is that the ratio of taurine 
conjugated CA versus MCA is reversed in the autophagy-deficient livers.  MCA is converted 
from chenodeoxycholic acid (CDCA), which is synthesized through both pathways (Fig. 
S2A).  On the other hand, CA is synthesized only through the classical pathway, for which 
Cyp8b1 is the key enzyme.  In autophagy deficient livers Cyp8b1 is significantly 
downregulated, thus favoring the generation of CDCA and MCA over CA, hence the higher 
ratio of TMCA/TCA.  This looks similar to what is observed in Cyp8b1-deficient mice (19).  
The reversion in TMCA/TCA ratio can contribute to the inhibition of FXR function as 
discussed above.  
 
It is noted that mice deficient in Fxr have key pathological features that are seen in the 
autophagy-deficient mice, including the significant downregulation of Bsep, abnormal 
expression of genes in bile acids synthesis, and elevated bile acids and cholesterol levels in 
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the blood (36).  But Fxr-deficient mice had no significant liver injury, perhaps owing to that 
Shp expression is not entirely dependent on Fxr and can be compensated in the absence of 
Fxr.  Consistently, mice deficient in both Fxr and Shp had severe liver injury (18), and both 
Fxr and Shp were downregulated in autophagy deficient livers (Fig. 6C, Fig. S4C).  
Additional mechanisms other than a simple reduction of Fxr can thus contribute to injury in 
autophagy-deficient livers (Fig. 8F).  
 
NRF2 contributes to liver pathology by repression of FXR in autophagy deficient 
livers  
Interestingly, co-deletion of Nrf2 reversed most, if not all, of the liver pathologies 
associated with defective hepatic autophagy (6-8), indicating that NRF2 is the master 
determining factor for the pathology of the liver.  However, the detrimental effect of NRF2 
had been puzzling since NRF2 is generally involved in protective anti-oxidative stress 
response (9-12).  The present study shows that a high level of NRF2 can contribute to the 
cholestatic injury of the liver, possibly by suppressing FXR functionality.  In addition, NRF2 
can cause HMGB1 release from autophagy-deficient hepatocytes, which contribute to the 
development of ductular reaction and tumor development in the livers (8).  NRF2 can thus act 
on multiple pathways to exert its pathological effects.   
 
Autophagy deficiency causes NRF2 to be highly activated due to displacement of KEAP1 
by the accumulated p62/SQSTM1 proteins (6).  NRF2 is best known for its ability to 
transcriptionally activate genes responsible for anti-oxidative stress (9-12) and genes 
involved in drug excretion (13), such as Nqo1, Mrp3 and Mrp4.  They are indeed elevated in 
autophagy deficient livers.  Sqstm1 is also upregulated by NRF2 (Fig. 6A, Fig. S5) as 
previously reported (6), but not by FXR in the autophagy deficient context, unlikely in other 
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contexts (39).  Most importantly, this study showed that activated NRF2 can cause 
transcriptional repression on genes such as Fxr.  The repressive effect of NRF2 on gene 
transcriptions has not been well studied.  The negative association with FXR expression 
provides a functionally relevant case for such investigations in future studies.   
 
The reversion of the injury by FXR activation also suggests that FXR suppression by 
NRF2 is a key mechanism in which NRF2 mediates cholestatic liver injury associated with 
disturbed bile acids metabolism (Fig.8F).  In addition, it should be noted that the detrimental 
effect of NRF2 needs to be distinguished from the reported protective effect of NRF2 in mice 
with normal autophagy function, but subjected to extra-hepatic cholestasis caused by bile 
duct ligation (40, 41).  Thus the overall effect of NRF2 activation in liver pathobiology would 
be context dependent.   
 
In summary, the present study has established a new regulatory pathway from autophagy 
to FXR via NRF2 and defined its significance in bile acids metabolism and in hepatic 
pathogenesis.  This is a new model in which autophagy regulates metabolism independently 
of the recycling of macromolecules for direct nutritional use, but by affecting a series of 
signaling events.  The autophagy-FXR regulatory loop may have important implications in 
metabolism broadly and in contexts other than autophagy deficiency or bile acids metabolism.   
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FIGURE LEGENDS 
Figure 1. Autophagy deficiency causes cholestasis.  
(A-C). Sera from mice of different genotypes were analyzed for the level of indicated 
parameters (n=3-7/group).  (D) Kinetic analysis of blood chemistry in Atg7
Hep-ERT2
 mice from 
D0 to D30 after induction of Atg7 deletion by tamoxifen (n=3/group).  (E) The amount of 
bile acids was determined in the liver, in the bile-containing gallbladder, and in the intestine 
of the Atg7-floxed and -deleted mice (n=8-12/group).  (F) The bile acids pool (gall bladder + 
liver + intestine), and the pool normalized with the body weight (n=8-11/group).  Atg7 F/F: 
Atg7-floxed control mice, Atg7-/-: hepatic Atg7-deficient mice, Nrf2-/-: Nrf2-deficient mice, 
Atg7/Nrf2-/-: Nrf2-deficient and hepatic Atg7-deficient mice.  *: p<0.05; ***: p<0.001; n.s.: 
no significance.   
Figure 2.  Autophagy deficiency leads to disturbance in bile acids metabolism.  
(A-C).The hepatic mRNA levels of indicated genes were quantified in 9-week old mice 
of different genotypes.  (D-E) The compositions of taurine-conjugated (D) and unconjugated 
(E) bile acids in the bile were analyzed.  *: p<0.05; **: p<0.01; ***: p<0.001; n. s.: no 
significance; n = 3 (A-C), or 4/group (D-E).   
Figure 3. Autophagy deficiency alters the expression of hepatocyte transporters. 
(A-B). Livers of 9 week-old mice of different genotypes were examined for BSEP by 
immunoblotting assay, which was quantified by densitometry.  (C). Liver sections from mice 
of different genotypes were immunostained with anti-BSEP.  Framed areas are enlarged and 
shown in separate panels (a-d).  Arrowheads and arrows represent different morphology of 
bile canalicular conduits between neighboring hepatocytes.  (D). The mRNA levels of 
indicated apical transporters were determined.  (E).The mRNA levels of the indicated 
basolateral systemic transporters were determined.  (F).The mRNA levels of the indicated 
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basolateral enterohepatic transporters were determined.  Atg5 F/F: Atg5-floxed control mice, 
Atg5-/-: hepatic Atg5-deficient mice.  *: p<0.05; **: p<0.01; ***: p<0.001.  n=3-5/group.   
Figure 4. Autophagy deficiency causes abnormality in bile canaliculi. 
(A). Liver sections from mice of different genotypes were immunostained with anti-
MRP2.  Framed areas are enlarged and shown in separate panels (a-d).  Arrows indicate 
enhanced signals of MRP2 in Atg7-deficient livers.  (B). Electron microscopic examination of 
the bile canaliculi in livers of different genotypes.  Two or three examples of the bile 
canaliculi in each genotype were shown.  Panels a1-a2 show normal canaliculi in the floxed 
Atg7 liver.  The example in panel a1 was enlarged in panel a1’.  Panel b1-b3 show enlarged 
and swollen bile canaliculi in Atg7-deficient liver, with the loss of microvilli and deposition 
of amorphous membranous materials.  Panels c1-c3 show largely normal bile canaliculi in 
Atg7/Nrf2-doubly deficient liver.  White arrow indicates the tight junction between the 
adherent hepatocytes.  BC: bile canaliculus.  (C). Livers from mice of different genotypes 
were sectioned and immunostained with an anti-ZO-1.  The framed areas were enlarged and 
displayed in subpanels (a-e).  Arrows indicated distorted ZO-1 staining pattern in Atg7-
deficient livers.  (D). Immunostaining with anti-β-CATENIN in Atg7-floxed and Atg7-
deficient livers.  (E). Livers sections were stained with rhodamine-phalloidin.  n =3/group.   
Figure 5. Autophagy regulates hepatic FXR expression. 
(A-B). Mice were given rapamycin (4 mg/kg, i.p. Rap) or subjected to starvation (Stv) for 
24 hours.  The hepatic protein level (A), or mRNA levels of Fxr and its targets (B) was 
determined.  Densitometry of the protein was conducted (A).  (C). Liver lysates from mice of 
given genotypes and ages (week) were examined by immunoblotting assay, and the relative 
expression levels were quantified by densitometry.  (D). Atg7
ΔHep-ERT2
 mice were given 4-
OHT on Day 1 and Day 2 to induce hepatic deletion of Atg7.  Group D0 were mice receiving 
vehicle control.  The livers were removed at different times (Day 5 to Day 20) and analyzed 
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by immunoblotting assay.  The densitometric levels of proteins shown in panel E were 
normalized to that of GAPDH, and to the Day 0 control group.  The liver/body ratio relative 
to that of Day 0, which is defined as 100%.  (E). Atg7
ΔHep-ERT2
 mice were given 4-OHT or 
vehicle as in panel E.  Mice were subjected to starvation (Stv) on Day 6 and analyzed 24 
hours later (Group D7).  Densitometry for the level of FXR was conducted.  *: p<0.05; **: 
p<0.01; n.s.: no significance;  n =3-5 mice/group.   
Figure 6. NRF2 is requried for FXR downreguation in autophagy deficient livers.  
(A-B). The hepatic protein (A) or mRNA (B) levels of FXR/Fxr were quantified in 9-
week old mice of different genotypes with or without Atg7 deficiency.  The protein level of 
FXR was quantified by densitometry.  (C) The hepatic mRNA levels of Fxr targets were 
determined in mice of different genotypes.  (D-E) Hepatic lysates from mice of different 
genotypes were subjected to CHIP analysis using an anti-FXR antibody or a control IgG.  
Quantitative PCR was performed using primers for the FXR-binding region in the promotors 
of Shp, Bsep or Ostβ (D), or primers for a coding region of Shp (E) as the control.  Data 
shown are average of three independent experiments.  * P<0.05, ** P<0.01, *** P<0.00, n.s.: 
no significance; n=3 (D-E) or 4 (B-C)/group.   
Figure 7. Stimulation of FXR reduces cholestatic liver injury. 
(A) The schedule for the treatment of Atg7-deficient mice with a FXR agonist, GW4064 
(30 mg/kg, i.p).  Control mice were given vehicle control (corn oil).  Mice were analyzed 2 
days after the last injection.  (B) Hepatic mRNA levels of indicated genes were analyzed.  (C) 
Liver lysates were analyzed by immunoblotting for BSEP, which was quantified by 
densitometry.  (D). Liver sections were immunostaining for BSEP.  Arrows indicate the 
typical cannalicular expression pattern of BSEP.  (E) Livers sections were subjected to the 
indicated staining (scale at x200 or as indicated).  Arrows indicate clusters of ductular cells, 
which was reduced in treated group.  (F). Atg7-floxed and -deleted mice treated with or 
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without GW4064 were analyzed for total blood bile acids, ALT levels and the liver/body 
weight ratio.  *: p<0.05; **: p<0.01; ***: p<0.001; n=6 mice/group.  
Figure 8.  Restoration of FXR expression reduces cholestasis in autphagy-deficient 
livers.   
(A). Schematic diagram showing the treatment of Atg7
Hep-ERT2
 mice with 4-OHT and 
adenovirus carrying VP16 or VP16-Fxr.  (B). The mRNA levels of indicated genes were 
analyzed by qRT-PCR in liver samples from Atg7
Hep-ERT2
mice receiving the designated 
treatment.  (C). Liver lysates were from Atg7
Hep-ERT2
 mice receiving the designated treatment 
were analyzed by immunoblotting assay.  (D). Livers from Atg7
Hep-ERT2
 mice receiving the 
designated treatment were stained with an anti-BSEP antibody (upper row) or Hematoxylin-
Eosin (lower row).  Arrows indicated the typical cannalicular pattern of BSEP distribution.  
(E). Serum total bile acid levels were determined.  (F). A model for the role of FXR in the 
liver injury caused by autophagy deficiency. Autophagy sustains FXR function whereas FXR 
suppresses autophagy at both fed and starved conditions, where FXR can be viewed as a 
feedback suppression mechanism for autophagy.  Downregulation of FXR during autophagy 
deficiency can lead to cholestasis, contributing to the liver injury.  NRF2 activation in 
autophagy deficiency can further enhance SQSTM1 expression and may cause additional 
insults to the liver.  *: p<0.05; **: p<0.01; ***: p<0.001; n = 4-5/group.   
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